Abstract
We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD). Memantine is indicated in the United States and Europe for moderate to severe AD, which is diagnosed if a patient has a Mini-Mental State Examination (MMSE) score of less than 15 or less than 20, respectively. Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD.
Original language | English |
---|---|
Pages (from-to) | 991-8 |
Number of pages | 8 |
Journal | Archives of Neurology |
Volume | 68 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2011 |